Negma Group
Finance · United Arab Emirates · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Dubai International Financial Center Icd...Phone Number
+971 43373035Website
www.negmagroup.comRevenue
<$5 MillionIndustry
About Negma Group
Negma Group Org Chart
Is Negma Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Negma Group recently announced quarterly report
Click to see if Negma Group had a recent Job posting/layoffs
Product Launch: Get notified when Negma Group launches new products
Funding: Get notified immidiatlly once Negma Group has new funding data
Congratulate Masked Content for being promoted to Masked Content at Negma Group
Negma Group, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Negma Group is spiking on competitors!
Check if Negma Group has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Negma Group is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Negma Group is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Negma Group.
Negma Group Tech Stack
A closer look at the technologies used by Negma Group
Negma Group News & Media
Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Negma Group
Negma Group is a diversified investment fund that specializes in debt and equity financing, venture capital funding, and quantitative trading strategies aimed at entrepreneurs and investors. Founded in 2013, the firm has deployed over 1 billion in capital commitments and financed 70 companies, achieving 50 successful ventures. With a focus on innov... Read More